Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Sees Significant Drop in Short Interest

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the recipient of a large decrease in short interest during the month of August. As of August 14th, there was short interest totaling 104,202 shares, a decrease of 41.3% from the July 30th total of 177,544 shares. Based on an average daily volume of 316,969 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.7% of the shares of the stock are short sold.

Institutional Trading of Enlivex Therapeutics

Several large investors have recently added to or reduced their stakes in ENLV. Renaissance Technologies LLC increased its stake in shares of Enlivex Therapeutics by 99.4% in the 4th quarter. Renaissance Technologies LLC now owns 313,628 shares of the company’s stock worth $221,000 after acquiring an additional 156,336 shares during the last quarter. Susquehanna International Group LLP increased its position in shares of Enlivex Therapeutics by 1,428.5% during the second quarter. Susquehanna International Group LLP now owns 157,648 shares of the company’s stock valued at $87,000 after acquiring an additional 147,334 shares during the last quarter. HRT Financial LP raised its position in Enlivex Therapeutics by 719.4% in the fourth quarter. HRT Financial LP now owns 153,990 shares of the company’s stock valued at $108,000 after purchasing an additional 135,198 shares during the period. Jane Street Group LLC raised its holdings in shares of Enlivex Therapeutics by 527.4% in the 1st quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock valued at $78,000 after buying an additional 67,886 shares during the period. Finally, Invesco Ltd. acquired a new stake in shares of Enlivex Therapeutics during the fourth quarter worth about $43,000. 1.02% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Zacks Research raised shares of Enlivex Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 21st. Wall Street Zen upgraded shares of Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Enlivex Therapeutics in a research note on Friday, June 26th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Enlivex Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $247.50.

Enlivex Therapeutics Stock Down 7.4%

Shares of Enlivex Therapeutics stock traded down $0.10 on Monday, hitting $1.25. 360,612 shares of the company were exchanged, compared to its average volume of 101,036. The company has a 50-day moving average price of $4.41 and a 200 day moving average price of $10.40. The stock has a market capitalization of $21.86 million, a price-to-earnings ratio of -0.15 and a beta of 1.60. Enlivex Therapeutics has a 1-year low of $1.15 and a 1-year high of $27.15.

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.